Leukaemia Trial, Recruiting NCT02863692 Sponsor: German CLL Study Group Condition: Leukaemia
Back to Leukaemia

Leukaemia Trial, Recruiting

NCT02863692
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a confirmed diagnosis of one of the following blood cancers: chronic lymphocytic leukaemia (CLL), B-cell or T-cell prolymphocytic leukaemia (B-PLL or T-PLL), small lymphocytic lymphoma (SLL), T-cell or NK-cell large granular lymphocytic leukaemia (T or NK-LGL), hairy cell leukaemia (HCL), or Richter's transformation
  • People who are 18 years of age or older
  • People who have signed a written consent form agreeing to take part
  • People who fall into at least one of the following situations: newly diagnosed and currently being monitored without treatment (a "watch and wait" approach, including within a clinical trial); currently receiving or having previously received standard approved treatments outside of a clinical trial; being assessed to see whether a stem cell transplant might be recommended; or having a disease that has come back after previous treatment (even if first diagnosed before this registry began)

Who may not be able to join:

  • People who do not have a confirmed diagnosis of one of the specific blood cancers listed above
  • People who have a condition affecting brain function, or who do not have the legal capacity to consent to participation

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Michael Hallek, MD, German CLL Study Group, Department I of Internal Medicine University Hospital Cologne

Phone: +4922147888220

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
German CLL Study Group
Registry
ClinicalTrials.gov
Start date
1 August 2013
Est. completion
1 December 2026

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov